Deep Track Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Deep Track Capital’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,158,041	Closed	-$125M	–	72
2026 Q1	$125M	Buy	3,158,041 +1,158,041	+58%	+$29.6M	2.05%	15
2025 Q4	$50M	Buy	+2,000,000	New	+$50.7M	0.89%	30
2025 Q3	–	Sell	-500,000	Closed	-$6.57M	–	59
2025 Q2	$6.57M	Buy	+500,000	New	+$6.33M	0.21%	48
2025 Q1	–	Sell	-1,350,000	Closed	-$22.6M	–	70
2024 Q4	$22.6M	Hold	1,350,000	–	–	0.84%	33
2024 Q3	$21.6M	Buy	+1,350,000	New	+$16.5M	0.68%	39
2022 Q1	–	Sell	-400,000	Closed	-$4.5M	–	58
2021 Q4	$4.5M	Buy	+400,000	New	+$5.38M	0.32%	49

Deep Track Capital's CNTA Position: Q2 2026 in Review

Deep Track Capital sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 3,158,041 shares — an estimated $125M sold.

Deep Track Capital first reported a position in CNTA in Q4 2021 and held it in 6 quarters. The position peaked at $125M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Deep Track Capital reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Deep Track Capital sold 3,158,041 Centessa Pharmaceuticals shares in Q2 2026, an estimated $125M.
Deep Track Capital first reported a position in Centessa Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Deep Track Capital's Centessa Pharmaceuticals position peaked at $125M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.